US4164566A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hepatitis a virus cell culture in vitro
Assignee: Merck and Co Inc
•
Filing: 1978-08-17
•
Granted: 1979-08-14
•
Expires: 1998-08-17
Abstract
Abstract Hepatitis A virus is passaged at least once in a susceptible sub-human primate; the infected liver from such passage is used to inoculate an in vitro cell culture, the inoculated cell culture is incubated until hepatitis A antigen is detected in the cell sheet or culture fluid, and at least two serial in vitro passages in cell culture are carried out. The hepatitis A virus so modified can be used to prepare live, attenuated hepatitis A vaccine or an inactivated hepatitis A vaccine.
Inventors
- 👤 Philip J. Provost
- 👤 Maurice R. Hilleman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 23:37
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; A61P; A61P31/00; A61P31/12; A61K2039/51; A61K2039/525; A61K2039/5252; A61K2039/5254; C; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/32011; C12N2770/32411; C12N2770/32434; C12N2770/32451; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
76 words
A method of growing hepatitis A virus in cell culture comprising modification of the virus by carrying out at least one passage of the virus in a susceptible sub-human primate, removing the infected liver, inoculating an in vitro cell culture with the infected liver, incubating the cell culture until hepatitis A antigen is detectable in the culture cells or fluid, and carrying out at least one additional in vitro passage of the virus in cell culture.
Claim 2
Independent Claim
76 words
A method of growing hepatitis A virus in cell culture comprising modification of the virus by carrying out at least one passage of the virus in a susceptible sub-human primate, removing the infected liver, inoculating an in vitro cell culture with the infected liver, incubating the cell culture until hepatitis A antigen is detectable in the culture cells or fluid, and carrying out at least one additional in vitro passage of the virus in cell culture.
Claim 3
Dependent Claim
30 words
A method according to claim 1 wherein the sub-human primate is a marmoset monkey, an owl monkey, a rhesus monkey, an African green monkey, a cynomolgus monkey, or a chimpanzee.
Claim 4
Dependent Claim
17 words
A method according to claim 2 wherein the marmoset monkey is Saguinus mystax or S. labiatus (rufiventer).
Claim 5
Dependent Claim
21 words
A method according to claim 1 wherein at least 5 passages of hepatitis A virus are carried out in sub-human primates.
Claim 6
Dependent Claim
24 words
A method according to claim 1 wherein the virus is passaged at least twice in each of two different species of susceptible sub-human primates.
Claim 7
Dependent Claim
24 words
A method according to claim 1 wherein the cell cultures consist of primary, continuously cultivated, or transformed cells derived from primate liver or kidney.
Claim 8
Dependent Claim
53 words
A method according to claim 1 wherein the hepatitis A virus is serially passaged at least 5 times in a cell culture suitable for human vaccine use, the cell culture being selected from human diploid lung fibroblasts, primary African green monkey kidney cells, primary chick embryo fibroblasts, or fetal rhesus diploid lung cells.
Claim 9
Dependent Claim
49 words
A live attenuated hepatitis A virus vaccine comprising an antigenic and immunogenic hepatitis A virus which has been modified by at least one passage in the liver of a sub-human primate susceptible to hepatitis A virus disease and by at least two serial in vitro passages in cell culture.
Claim 10
Dependent Claim
49 words
A live attenuated hepatitis A virus vaccine comprising an antigenic and immunogenic hepatitis A virus which has been modified by at least one passage in the liver of a sub-human primate susceptible to hepatitis A virus disease and by at least two serial in vitro passages in cell culture.
Claim 11
Dependent Claim
26 words
The hepatitis A virus vaccine according to claim 8 in which the virus has been inactivated by contact with an agent effective to inactivate the virus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-08-13 | 1983-02-12 | 1983-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-08-13 | 1987-02-12 | 1987-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-08-13 | 1991-02-12 | 1991-08-14 | $7700.00 | Window Closed / Lapsed |